This is Reshma Kewalramani’s second consecutive year on the STATUS List, a testament to just how much impact the Vertex CEO continues to make in drug development. In recent months, regulators in the U.K. and U.S. gave the world’s first approvals to a CRISPR-based medicine: Casgevy, made by Vertex and CRISPR Therapeutics to treat and potentially cure sickle cell disease as well as beta thalassemia. Casgevy’s commercial launch will be closely watched in the year ahead. As Adam Feuerstein noted when he named Kewalramani to his list of the best biotech CEOs of 2023, Vertex is also making progress on VX-548, a non-addictive painkiller that it hopes will be a safe and effective alternative to opioids. It announced in January that VX-548 had succeeded in late-stage trials — a potential game-changer in a country where more than 75% of overdose deaths involved opioids.
Industry
Location
-
Boston, Mass.
